MedTrace Logo

Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia

NCT07263906 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-12-04

No results posted yet for this study

Summary

This study aims to evaluate the safety and efficacy of LILRA6-directed chimeric antigen receptor T cells (LILRA6 CAR-T cells) in patients with refractory or relapsed acute myeloid leukemia(AML).

Conditions

  • Refractory Acute Myeloid Leukemia
  • Recurrent Acute Myeloid Leukemia

Interventions

BIOLOGICAL

Anti-LILRA6 CAR-T cells

lentiviral vector-transducted peripheral blood-derived T cells to express anti-LILRA6 CAR

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Wenbin Qian, Professor · Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2027-10-01
Completion
2028-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07263906 on ClinicalTrials.gov